Portfolio company
Actuate Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops elraglusib, a small-molecule GSK-3 inhibitor, for patients with metastatic pancreatic cancer and other refractory solid tumours.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Akiram Therapeutics
This biotech company develops targeted radiopharmaceuticals and radioimmunotherapies for patients with solid tumours and metastatic cancers.
Actithera Group
This company develops radioligand therapies to treat cancer patients by delivering radiation directly to solid tumours while sparing healthy tissue.
Actym Therapeutics
This biotechnology company develops bacterial immunotherapies to treat solid tumours and fibrotic diseases for patients with advanced cancers.
MyCural Therapeutics
This company develops small molecule drugs targeting the MYC oncoprotein to treat patients with aggressive, high-risk cancers.
Mirati
This biotechnology company develops targeted oncology therapies and small molecule inhibitors for patients with lung, colorectal and pancreatic cancers.
ARase Therapeutics
This company develops small molecule drugs targeting ADP-ribose hydrolases for patients with various forms of cancer.
THERAtRAME
The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.
AbilityPharma
This company develops autophagy-inducing oral therapies for patients with various forms of cancer, including pancreatic, endometrial and lung cancer.